Trade Palisade Bio, Inc. - PALI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.55 |
Open* | 0.55 |
1-Year Change* | 30.95% |
Day's Range* | 0.52 - 0.55 |
52 wk Range | 0.07-2.86 |
Average Volume (10 days) | 2.02M |
Average Volume (3 months) | 123.43M |
Market Cap | 5.83M |
P/E Ratio | 0.22 |
Shares Outstanding | 71.24M |
Revenue | N/A |
EPS | 0.37 |
Dividend (Yield %) | N/A |
Beta | 1.80 |
Next Earnings Date | Mar 16, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 21, 2023 | 0.55 | -0.02 | -3.51% | 0.57 | 0.57 | 0.54 |
Sep 20, 2023 | 0.57 | 0.00 | 0.00% | 0.57 | 0.57 | 0.56 |
Sep 19, 2023 | 0.56 | -0.01 | -1.75% | 0.57 | 0.58 | 0.55 |
Sep 18, 2023 | 0.58 | -0.01 | -1.69% | 0.59 | 0.60 | 0.57 |
Sep 15, 2023 | 0.59 | -0.01 | -1.67% | 0.60 | 0.60 | 0.58 |
Sep 14, 2023 | 0.60 | 0.00 | 0.00% | 0.60 | 0.63 | 0.58 |
Sep 13, 2023 | 0.62 | -0.05 | -7.46% | 0.67 | 0.67 | 0.61 |
Sep 12, 2023 | 0.66 | -0.03 | -4.35% | 0.69 | 0.69 | 0.61 |
Sep 11, 2023 | 0.70 | 0.00 | 0.00% | 0.70 | 0.73 | 0.68 |
Sep 8, 2023 | 0.73 | 0.02 | 2.82% | 0.71 | 0.78 | 0.68 |
Sep 7, 2023 | 0.76 | -0.05 | -6.17% | 0.81 | 0.85 | 0.68 |
Sep 6, 2023 | 1.41 | -0.13 | -8.44% | 1.54 | 1.90 | 1.33 |
Sep 5, 2023 | 0.66 | 0.01 | 1.54% | 0.65 | 0.66 | 0.64 |
Sep 1, 2023 | 0.64 | 0.00 | 0.00% | 0.64 | 0.65 | 0.62 |
Aug 31, 2023 | 0.66 | 0.00 | 0.00% | 0.66 | 0.66 | 0.65 |
Aug 30, 2023 | 0.68 | 0.07 | 11.48% | 0.61 | 0.69 | 0.60 |
Aug 29, 2023 | 0.62 | 0.02 | 3.33% | 0.60 | 0.63 | 0.60 |
Aug 28, 2023 | 0.60 | 0.02 | 3.45% | 0.58 | 0.60 | 0.58 |
Aug 25, 2023 | 0.58 | -0.01 | -1.69% | 0.59 | 0.60 | 0.58 |
Aug 24, 2023 | 0.58 | -0.02 | -3.33% | 0.60 | 0.61 | 0.58 |
Palisade Bio, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, November 13, 2023 | ||
Time (UTC) 13:30 | Country US
| Event Q3 2023 Palisade Bio Inc Earnings Release Q3 2023 Palisade Bio Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 0 | 0.01352 | 0.01539 | 0.26 | 0.26 |
Revenue | 0.01352 | 0.01539 | 0.26 | 0.26 | |
Total Operating Expense | 42.261 | 10.6891 | 8.64709 | 8.51946 | 13.5671 |
Selling/General/Admin. Expenses, Total | 9.307 | 8.67061 | 4.58564 | 4.55927 | 5.47101 |
Research & Development | 2.43 | 2.01845 | 4.06145 | 3.96019 | 8.0961 |
Operating Income | -42.261 | -10.6756 | -8.6317 | -8.25946 | -13.3071 |
Interest Income (Expense), Net Non-Operating | 20.635 | 0.02881 | 0.55795 | 3.34023 | -1.55898 |
Other, Net | -4.99 | -5.62009 | -0.27791 | -0.00539 | -0.79991 |
Net Income Before Taxes | -26.616 | -16.2668 | -8.35165 | -4.92462 | -15.666 |
Net Income After Taxes | -26.616 | -16.2668 | -8.35165 | -4.92462 | -15.666 |
Net Income Before Extra. Items | -26.616 | -16.2668 | -8.35165 | -4.92462 | -15.666 |
Net Income | -26.616 | -16.2668 | -8.35165 | -4.92462 | -15.666 |
Income Available to Common Excl. Extra. Items | -26.616 | -16.2668 | -8.35165 | -4.92462 | -15.666 |
Income Available to Common Incl. Extra. Items | -26.616 | -16.2668 | -8.35165 | -4.92462 | -15.666 |
Diluted Net Income | -26.616 | -16.2668 | -8.35165 | -4.92462 | -15.666 |
Diluted Weighted Average Shares | 9.30977 | 2.31155 | 0.36625 | 0.12631 | 0.10887 |
Diluted EPS Excluding Extraordinary Items | -2.85893 | -7.03721 | -22.8034 | -38.9883 | -143.893 |
Diluted Normalized EPS | 0.41977 | -7.03721 | -22.8034 | -38.9883 | -143.893 |
Unusual Expense (Income) | 30.524 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 3.888 | 4.027 | 3.016 | 32.858 | 2.36 |
Selling/General/Admin. Expenses, Total | 2.929 | 3.227 | 2.392 | 2.427 | 1.261 |
Research & Development | 0.959 | 0.8 | 0.624 | 0.314 | 0.692 |
Unusual Expense (Income) | 0 | 0 | 0 | 30.117 | 0.407 |
Operating Income | -3.888 | -4.027 | -3.016 | -32.858 | -2.36 |
Interest Income (Expense), Net Non-Operating | 0.792 | 5.089 | 12.738 | 4.478 | -1.67 |
Other, Net | -1.109 | 0.011 | -1.635 | -3.366 | 0 |
Net Income Before Taxes | -4.205 | 1.073 | 8.087 | -31.746 | -4.03 |
Net Income After Taxes | -4.205 | 1.073 | 8.087 | -31.746 | -4.03 |
Net Income Before Extra. Items | -4.205 | 1.073 | 8.087 | -31.746 | -4.03 |
Net Income | -4.205 | 1.073 | 8.087 | -31.746 | -4.03 |
Income Available to Common Excl. Extra. Items | -4.205 | 1.073 | 8.087 | -31.746 | -4.03 |
Income Available to Common Incl. Extra. Items | -4.205 | 1.073 | 8.087 | -31.746 | -4.03 |
Diluted Net Income | -4.205 | 1.073 | 8.087 | -31.746 | -4.03 |
Diluted Weighted Average Shares | 16.2237 | 13.5328 | 12.1068 | 8.9842 | 7.43177 |
Diluted EPS Excluding Extraordinary Items | -0.25919 | 0.07929 | 0.66797 | -3.53354 | -0.54227 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.25919 | 0.07929 | 0.66797 | -0.18132 | -0.4875 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 12.374 | 12.8808 | 5.64688 | 6.50839 | 12.4488 |
Cash and Short Term Investments | 10.495 | 10.5292 | 5.11492 | 5.78711 | 11.6749 |
Cash & Equivalents | 10.495 | 10.5292 | 5.11492 | 5.78711 | 6.67494 |
Short Term Investments | 0 | 5 | |||
Total Receivables, Net | 0.15 | 0.11628 | 0.02106 | 0.358 | 0.37159 |
Accounts Receivable - Trade, Net | 0 | 0.11628 | 0.02106 | 0.29406 | 0.3128 |
Prepaid Expenses | 1.703 | 1.39979 | 0.5109 | 0.36329 | 0.40227 |
Total Assets | 12.512 | 13.0491 | 6.58389 | 7.68445 | 13.8845 |
Property/Plant/Equipment, Total - Net | 0.112 | 0.01078 | 0.04104 | 0.09031 | 0.17289 |
Property/Plant/Equipment, Total - Gross | 0.99145 | 0.99481 | |||
Accumulated Depreciation, Total | -0.95042 | -0.82193 | |||
Intangibles, Net | 0.14713 | 0.66894 | 0.76354 | 0.88346 | |
Note Receivable - Long Term | 0 | 0.29824 | 0.36546 | ||
Other Long Term Assets, Total | 0.026 | 0.01044 | 0.22704 | 0.02397 | 0.01385 |
Total Current Liabilities | 2.496 | 3.20593 | 1.22476 | 1.05117 | 1.51457 |
Payable/Accrued | 0.64935 | 0.82441 | 0.83256 | 0.87507 | |
Accrued Expenses | 1.086 | 2.32224 | 0.13569 | 0 | 0.41863 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.087 | 0 | |||
Other Current Liabilities, Total | 0.23434 | 0.26467 | 0.2186 | 0.22088 | |
Total Liabilities | 5.147 | 3.28123 | 1.4579 | 1.6349 | 5.36933 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | ||||
Other Liabilities, Total | 2.651 | 0.0753 | 0.23314 | 0.58373 | 3.85476 |
Total Equity | 7.365 | 9.76792 | 5.12599 | 6.04955 | 8.51513 |
Preferred Stock - Non Redeemable, Net | 0.002 | 0.002 | 0.002 | 0.01 | 0.01 |
Common Stock | 0.143 | 0.17296 | 0.03867 | 0.18205 | 0.1516 |
Additional Paid-In Capital | 101.862 | 247.836 | 227.067 | 219.482 | 217.05 |
Retained Earnings (Accumulated Deficit) | -94.642 | -238.242 | -221.976 | -213.624 | -208.699 |
Other Equity, Total | -0.00073 | -0.00619 | -0.00041 | 0.00263 | |
Total Liabilities & Shareholders’ Equity | 12.512 | 13.0491 | 6.58389 | 7.68445 | 13.8845 |
Total Common Shares Outstanding | 14.2392 | 2.88268 | 0.64442 | 0.15171 | 0.12634 |
Total Preferred Shares Outstanding | 0.2 | 0.2 | 0.2 | 1 | 1 |
Other Current Assets, Total | 0.026 | 0.83548 | |||
Accounts Payable | 1.323 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 8.258 | 12.374 | 16.092 | 14.725 | 8.7556 |
Cash and Short Term Investments | 6.644 | 10.495 | 14.104 | 12.653 | 6.56095 |
Cash & Equivalents | 6.644 | 10.495 | 14.104 | 12.653 | 6.56095 |
Total Receivables, Net | 0.086 | 0 | 0 | 0.059 | 0.02526 |
Accounts Receivable - Trade, Net | 0 | 0 | 0.059 | 0.02526 | |
Prepaid Expenses | 1.42 | 1.879 | 1.988 | 2.013 | 1.30869 |
Other Current Assets, Total | 0.108 | 0.8607 | |||
Total Assets | 8.35 | 12.512 | 16.274 | 14.949 | 8.91492 |
Property/Plant/Equipment, Total - Net | 0.066 | 0.112 | 0.156 | 0.198 | 0.00724 |
Intangibles, Net | 0.14164 | ||||
Other Long Term Assets, Total | 0.026 | 0.026 | 0.026 | 0.026 | 0.01044 |
Total Current Liabilities | 1.864 | 2.496 | 2.92 | 3.85 | 1.01493 |
Payable/Accrued | 0.52091 | ||||
Accrued Expenses | 0.717 | 1.086 | 0.969 | 1.303 | 0.31626 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.17776 | ||||
Total Liabilities | 3.558 | 5.147 | 12.354 | 24.393 | 1.18613 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 1.694 | 2.651 | 9.434 | 20.543 | 0.1712 |
Total Equity | 4.792 | 7.365 | 3.92 | -9.444 | 7.72879 |
Preferred Stock - Non Redeemable, Net | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Common Stock | 0.183 | 0.143 | 0.13 | 0.114 | 0.02883 |
Additional Paid-In Capital | 103.454 | 101.862 | 99.503 | 94.242 | 248.228 |
Retained Earnings (Accumulated Deficit) | -98.847 | -94.642 | -95.715 | -103.802 | -240.527 |
Other Equity, Total | -0.00278 | ||||
Total Liabilities & Shareholders’ Equity | 8.35 | 12.512 | 16.274 | 14.949 | 8.91492 |
Total Common Shares Outstanding | 18.2335 | 14.2392 | 12.9299 | 11.3987 | 2.88262 |
Total Preferred Shares Outstanding | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
Accounts Payable | 1.147 | 1.323 | 1.383 | 1.406 | |
Current Port. of LT Debt/Capital Leases | 0 | 0.087 | 0.568 | 1.141 | |
Long Term Debt | 0 | 0 | 0 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -26.616 | -16.2668 | -8.35165 | -4.92462 | -15.666 |
Cash From Operating Activities | -14.773 | -9.02513 | -7.25568 | -7.69242 | -13.4162 |
Cash From Operating Activities | 0.002 | 0.09227 | 0.14386 | 0.1858 | 0.28921 |
Non-Cash Items | 16.597 | 6.19578 | 0.74383 | -2.61672 | 4.11447 |
Cash Taxes Paid | 0 | ||||
Changes in Working Capital | -4.756 | 0.95364 | 0.20829 | -0.33688 | -2.15385 |
Cash From Investing Activities | -0.054 | 0 | 4.99829 | -0.09405 | |
Capital Expenditures | 0 | -0.00171 | -0.09405 | ||
Other Investing Cash Flow Items, Total | -0.054 | 0 | 5 | 0 | |
Cash From Financing Activities | 24.609 | 14.4659 | 6.58951 | 1.81423 | 4.99078 |
Financing Cash Flow Items | -0.218 | ||||
Issuance (Retirement) of Stock, Net | 25.01 | 14.6982 | 6.55308 | 1.828 | 8.73602 |
Issuance (Retirement) of Debt, Net | -0.183 | -0.2323 | 0.03643 | -0.01377 | -3.74524 |
Foreign Exchange Effects | -0.00119 | -0.00602 | -0.00793 | -0.00058 | |
Net Change in Cash | 9.782 | 5.4396 | -0.67219 | -0.88783 | -8.52001 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.205 | -26.616 | -27.689 | -35.776 | -2.28508 |
Cash From Operating Activities | -3.764 | -14.773 | -11.718 | -8.972 | -3.94124 |
Cash From Operating Activities | 0.001 | 0.002 | 0.002 | 0.002 | 0.00903 |
Non-Cash Items | 0.72 | 16.597 | 21.342 | 32.167 | 0.3439 |
Changes in Working Capital | -0.28 | -4.756 | -5.373 | -5.365 | -2.00908 |
Cash From Investing Activities | 0 | -0.054 | -0.054 | 0.294 | 0 |
Other Investing Cash Flow Items, Total | 0 | -0.054 | -0.054 | 0.294 | 0 |
Cash From Financing Activities | -0.087 | 24.609 | 25.163 | 20.618 | 0 |
Issuance (Retirement) of Stock, Net | 25.01 | 25.01 | 19.801 | 0 | |
Issuance (Retirement) of Debt, Net | -0.087 | -0.183 | 0.301 | 0.965 | 0 |
Foreign Exchange Effects | -0.00104 | ||||
Net Change in Cash | -3.851 | 9.782 | 13.391 | 11.94 | -3.94228 |
Capital Expenditures | 0 | ||||
Financing Cash Flow Items | -0.218 | -0.148 | -0.148 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Palisade Bio, Inc. Company profile
About Palisade Bio Inc
Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Palisade Bio Inc revenues decreased from $11K to $0K. Net loss increased from $11.8M to $27.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest expense increase from $14K to $2.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$7.31 to -$3.41.
Equity composition
Common Stock $.01 Par, 03/11, 150M auth., 48,366,304 shares issd. Insiders & Strategic holders own 13.61%. IPO:1/07, 16.3M shares @ $1 per Share.
Industry: | Biotechnology & Medical Research (NEC) |
7750 El Camino Real, Suite 5200
92009
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com